PDCD1 and acute myeloid leukemia: Additionally, research indicates that the application of ICIs targeting PD-1 (nivolumab) or CTLA-4 (ipilimumab) before stem cell transplantation (SCT) can enhance the progression-free survival (PFS) of AML/MDS patients post-transplant [61].